GoAI
Get started
OrthoPediatrics Corp. logo

OrthoPediatrics Corp.

KIDS

NASDAQHealthcareMedical - Devices

Open in GoAI

Previous close

$25.65

−$0.58 · -2.21%

Aug 21, 4:00 PM ET

KIDS company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

47

Fair Value

Momentum

53

Neutral

Sentiment

62

Bullish

Risk resilience

57

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

OrthoPediatrics Corp. is a medical technology firm dedicated to the design, development, and global commercialization of specialized implants and devices. These products are meticulously crafted to be anatomically appropriate for treating children affected by orthopedic conditions across the United States and internationally. The company's diverse offerings span products for trauma and deformity correction, surgical systems for spinal deformities such as scoliosis, and solutions for sports medicine, among others. Their comprehensive product line features items like PediLoc, PediPlates, various cannulated screws, the PediFlex and PediNail systems, PediLoc tibia, advanced anterior cruciate ligament reconstruction systems, specialized locking cannulated blades and proximal femurs, Spica Tables, RESPONSE Spine systems, Bandloc, Pediguard, the Pediatric Nailing Platform, Femur system, Orthex, QuickPack, and the ApiFix Mid-C system. OrthoPediatrics Corp. primarily serves the pediatric orthopedic market, directly assisting pediatric orthopedic surgeons and caregivers. The company was founded in 2006 and maintains its headquarters in Warsaw, Indiana.

Industry
Medical - Devices
Sector
Healthcare
Headquarters
US
CEO
David R. Bailey
Listed since
Oct 13, 2017
Employees
602

Market position

Day range

Current $25.65

52-week range

Current $25.65

Open
$26.23
Previous close
$26.23
Volume
364.62K
2× average
Average volume
182.41K
Average daily volume
Market cap
658.82M USD
Beta
0.97
Market reference 1
50-day average
$20.7908
+23.37% above average
200-day average
$18.2011
+40.93% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
497.07M USD
P/E (TTM)
-15.27×
P/B (TTM)
1.78×
P/S (TTM)
2.61×
EV / EBITDA
-41.62×
Earnings yield
-9.52%
Free cash flow yield
-3.83%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
73.65%
Operating margin
-9.01%
Net margin
-15.72%
Return on equity
-11.44%
Return on assets
-7.80%
Return on invested capital
-6.27%

Financial health

Debt / equity
0.27×
Current ratio
5.55×
Altman Z-score
2.34
Piotroski F-score
5 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends84%46%8%-30%Gross margin, FY2021: 74.86%Gross margin, FY2022: 74.14%Gross margin, FY2023: 74.80%Gross margin, FY2024: 72.58%Gross margin, FY2025: 73.05%Operating margin, FY2021: -18.38%Operating margin, FY2022: -20.77%Operating margin, FY2023: -17.99%Operating margin, FY2024: -14.42%Operating margin, FY2025: -12.27%Net margin, FY2021: -16.58%Net margin, FY2022: 1.03%Net margin, FY2023: -14.10%Net margin, FY2024: -18.47%Net margin, FY2025: -16.78%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 74.86%. Gross margin FY2022 74.14%. Gross margin FY2023 74.80%. Gross margin FY2024 72.58%. Gross margin FY2025 73.05%. Operating margin FY2021 -18.38%. Operating margin FY2022 -20.77%. Operating margin FY2023 -17.99%. Operating margin FY2024 -14.42%. Operating margin FY2025 -12.27%. Net margin FY2021 -16.58%. Net margin FY2022 1.03%. Net margin FY2023 -14.10%. Net margin FY2024 -18.47%. Net margin FY2025 -16.78%.

Income trends

Revenue

236.35M USD+15.45%

Operating income

−29M USD+1.77%

Net income

−39.65M USD-4.83%
Income trends across reported periods263.95M USD153.55M USD43.15M USD−67.25M USDRevenue, FY2021: 98.05M USDRevenue, FY2022: 122.29M USDRevenue, FY2023: 148.73M USDRevenue, FY2024: 204.73M USDRevenue, FY2025: 236.35M USDOperating income, FY2021: −18.02M USDOperating income, FY2022: −25.4M USDOperating income, FY2023: −26.75M USDOperating income, FY2024: −29.52M USDOperating income, FY2025: −29M USDNet income, FY2021: −16.26M USDNet income, FY2022: 1.26M USDNet income, FY2023: −20.97M USDNet income, FY2024: −37.82M USDNet income, FY2025: −39.65M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 98.05M USD. Revenue FY2022 122.29M USD. Revenue FY2023 148.73M USD. Revenue FY2024 204.73M USD. Revenue FY2025 236.35M USD. Operating income FY2021 −18.02M USD. Operating income FY2022 −25.4M USD. Operating income FY2023 −26.75M USD. Operating income FY2024 −29.52M USD. Operating income FY2025 −29M USD. Net income FY2021 −16.26M USD. Net income FY2022 1.26M USD. Net income FY2023 −20.97M USD. Net income FY2024 −37.82M USD. Net income FY2025 −39.65M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue236.35M USD204.73M USD148.73M USD122.29M USD98.05M USD
Cost of goods sold63.69M USD56.13M USD37.48M USD31.63M USD24.65M USD
Gross profit172.66M USD148.6M USD111.25M USD90.66M USD73.4M USD
Research and development9.1M USD11.03M USD10.9M USD8.45M USD5.54M USD
Selling, general, and administrative192.56M USD167.09M USD126.12M USD104M USD85.73M USD
Operating expenses201.66M USD178.12M USD138M USD116.06M USD91.43M USD
Interest income——198K USD——
Interest expense6M USD2.62M USD—2.42M USD2.25M USD
Depreciation and amortization21.25M USD19.08M USD17.39M USD13.1M USD10.68M USD
Operating income−29M USD−29.52M USD−26.75M USD−25.4M USD−18.02M USD
Net income−39.65M USD−37.82M USD−20.97M USD1.26M USD−16.26M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
64%
7 beats, 4 misses, 0 met estimates
Average EPS surprise
+1.32%
11 comparable reports
Latest EPS result
-0.26
Estimate -0.3 · Beat by 13.97%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.09-0.22-0.34-0.47Q1 '25BeatQ2 '25MissQ3 '25BeatQ4 '25BeatQ1 '26MissQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 4, 2025: actual -0.29, estimate -0.33, surprise +12.12%, Beat. Q2 2025, reported May 7, 2025: actual -0.39, estimate -0.26, surprise -50.00%, Miss. Q3 2025, reported Aug 5, 2025: actual -0.11, estimate -0.17, surprise +35.29%, Beat. Q4 2025, reported Oct 28, 2025: actual -0.24, estimate -0.26, surprise +7.69%, Beat. Q1 2026, reported Feb 26, 2026: actual -0.43, estimate -0.37, surprise -16.22%, Miss. Q2 2026, reported Apr 30, 2026: actual -0.42, estimate -0.38, surprise -10.53%, Miss. Q3 2026, reported Aug 4, 2026: actual -0.26, estimate -0.302, surprise +13.97%, Beat. Q4 2026, reported Oct 27, 2026: actual —, estimate -0.25, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates73.33M65.17M57.02M48.86MQ1 '25MissQ2 '25BeatQ3 '25MissQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 4, 2025: actual 52.67M USD, estimate 52.98M USD, surprise -0.60%, Miss. Q2 2025, reported May 7, 2025: actual 52.41M USD, estimate 51.68M USD, surprise +1.41%, Beat. Q3 2025, reported Aug 5, 2025: actual 61.08M USD, estimate 61.4M USD, surprise -0.52%, Miss. Q4 2025, reported Oct 28, 2025: actual 61.25M USD, estimate 59.28M USD, surprise +3.33%, Beat. Q1 2026, reported Feb 26, 2026: actual 61.61M USD, estimate 60.16M USD, surprise +2.40%, Beat. Q2 2026, reported Apr 30, 2026: actual 59.36M USD, estimate 58.29M USD, surprise +1.85%, Beat. Q3 2026, reported Aug 4, 2026: actual 70.51M USD, estimate 68.21M USD, surprise +3.37%, Beat. Q4 2026, reported Oct 27, 2026: actual —, estimate 68.49M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

13 ratings
Strong buy00%
Buy1292%
Hold18%
Sell00%
Strong sell00%

KIDS news

marketbeat.com

OrthoPediatrics Sees ‘Inflection Point' as New Products Fuel Record Quarter

OrthoPediatrics NASDAQ: KIDS reported record revenue, adjusted EBITDA and number of children helped during the second quarter, as the pediatric orthopedic device company began to see early contributions from its newer…

Read source
gurufocus.com

Intercontinental Exchange Reports July 2026 Statistics

Intercontinental Exchange, Inc. (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets, today

Read source
seekingalpha.com

OrthoPediatrics Corp. (KIDS) Q2 2026 Earnings Call Transcript

OrthoPediatrics Corp. (KIDS) Q2 2026 Earnings Call Transcript

Read source
marketbeat.com

OrthoPediatrics Q2 Earnings Call Highlights

OrthoPediatrics NASDAQ: KIDS reported record second-quarter revenue of $70.5 million, up 15% from a year earlier, as strong Trauma & Deformity and specialty bracing performance offset a reported decline in scoliosis…

Read source
zacks.com

OrthoPediatrics (KIDS) Reports Q2 Loss, Tops Revenue Estimates

OrthoPediatrics (KIDS) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to a loss of $0.11 per share a year ago.

Read source
globenewswire.com

OrthoPediatrics Corp. Reports Second Quarter 2026 Financial Results and Increases 2026 Financial Guidance

WARSAW, Ind., Aug. 04, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced…

Read source

KIDS peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding KIDS

Funds reporting this stock among their holdings, ordered by reported position size.

iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
11.48M
Weight
0.01%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
10.79M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
4.13M
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Russell 2000 Value ETF logoiShares Russell 2000 Value ETFIWN
Market value
3.07M
Weight
0.02%
AUM
14.66B USD
Expense ratio
0.24%
Price / 1D
$224.81+0.45%
Schwab U.S. Small-Cap ETF logoSchwab U.S. Small-Cap ETFSCHA
Market value
2.1M
Weight
0.01%
AUM
23.1B USD
Expense ratio
0.03%
Price / 1D
$34.83+0.52%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
2.01M
Weight
0.01%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%
U.S. Micro Cap Portfolio ETF logoU.S. Micro Cap Portfolio ETFDFMC
Market value
1.75M
Weight
0.02%
AUM
8.06B USD
Expense ratio
0.43%
Price / 1D
$60.95+0.73%
Dimensional - US Core Equity 2 ETF logoDimensional - US Core Equity 2 ETFDFAC
Market value
1.6M
Weight
0.00%
AUM
49.31B USD
Expense ratio
0.17%
Price / 1D
$45.61+0.46%

Continue in GoAI

Research KIDS

research.disclaimer